Consistent with the results shown in Table 1, we found that 80.8% of HER2+ patients with high residual tumour (RCB-II/III) were ER positive, which contributed to the association between ER expression and RCB (p = 0.046). The gene discussed is ESR1; the disease is neoplasm.